Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | CASP1 | P29466 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30209768 | 1.00 | SMN1; SMN2 (0.59) | SMN1; SMN2TSHRCASP1ALDH1A1MAPK1 | |
| SCHEMBL13494354 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2TSHRCASP1ALDH1A1MAPK1 | |
| SCHEMBL3130853 | 0.86 | SMN1; SMN2 (0.57) | SMN1; SMN2TSHRCASP1ALDH1A1MAPK1 | |
| SCHEMBL1922201 | 0.85 | SMN1; SMN2 (0.55) | SMN1; SMN2TSHRCASP1ALDH1A1MAPK1 | |
| SCHEMBL8168081 | 0.84 | ALDH1A1 (0.59) | SMN1; SMN2TSHRCASP1ALDH1A1MAPT | |
| SCHEMBL9652056 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2TSHRCASP1ALDH1A1MAPK1 | |
| SCHEMBL14039216 | 0.82 | HPGD (0.47) | SMN1; SMN2ALDH1A1MAPTKMT2AMEN1 | |
| SCHEMBL12438177 | 0.82 | HSD17B10 (0.45) | SMN1; SMN2TSHRALDH1A1MAPTKDM4E | |
| SCHEMBL12438178 | 0.82 | KDM4E (0.47) | SMN1; SMN2TSHRCASP1ALDH1A1HIF1A | |
| SCHEMBL13494263 | 0.82 | SMN1; SMN2 (0.52) | SMN1; SMN2TSHRCASP1ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. | 2023-07-27 | — | — | US | disclosed |
| EP-4157821-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | Constellation Pharmaceuticals, Inc. (US) | 2023-04-05 | — | — | EP | disclosed |
| CN-115867535-A | Substituted benzamides as modulators of TREX1 | 星座制药公司 | 2023-03-28 | — | — | CN | disclosed |
| WO-2021243001-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| WO-2021243001-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732029-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-15 | — | — | US | disclosed |
| US-9725402-B2 | Nitroso compounds as nitroxyl donors and methods of use thereof | CARDIOXYL PHARMACEUTICALS, INC. (US) | 2017-08-08 | — | — | US | disclosed |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION | 2007-10-04 | — | — | US | disclosed |
| US-7244721-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION CORVAS INTERNATIONAL, LTD. | 2007-02-08 | — | — | US | disclosed |
| US-7169760-B2 | Peptides as NS3-serine protease inhibitors of hepatitis C virus | SCHERING CORPORATION (US) | 2007-01-30 | — | — | US | disclosed |
| US-6093851-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LTD. (JP) | 2000-07-25 | — | — | US | disclosed |
| EP-0735018-B1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL CO (JP) | 1999-07-21 | — | — | EP | disclosed |
| US-5739401-A | N-(α-alkylbenzylidene)-α-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-04-14 | — | — | US | disclosed |
| EP-0735018-A1 | N-(alpha-alkylbenzylidene)-alpha-phenylalkylamine, its use and process for producing the same and process for producing intermediate therefor | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 1996-10-02 | — | — | EP | disclosed |
| US-5159089-A | Using a sulfur methylide compound | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1992-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233541-A1 | SUBSTITUTED BENZAMIDES AS MODULATORS OF TREX1 | TREH, BRIX1, GBA1 | SMN1; SMN2 373/4885TSHR 1161/4885CASP1 514/4885 |
| US-20070232549-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SMN1; SMN2 3286/4885TSHR 4691/4885CASP1 416/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | SMN1; SMN2 2049/4885TSHR 1602/4885CASP1 855/4885 |
| US-20070032433-A1 | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus | HPN, TMPRSS15, VIP | SMN1; SMN2 3286/4885TSHR 4691/4885CASP1 416/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.